---
title: "A Top Wall Street Analyst 'Can't Ignore' Celldex Stock (CLDX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283370239.md"
description: "Celldex (CLDX) stock received a double upgrade from Barclays analyst Etzer Darout, raising its rating to Overweight and price target to $45 from $25, indicating a potential 30.25% upside. This upgrade follows positive results from its Phase 3 clinical trial for barzolvolimab, which showed strong demand. Despite a premarket rally, the stock is slightly down today but has risen 27.21% year-to-date and 82.42% over the past year, with trading volume below average."
datetime: "2026-04-20T14:19:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283370239.md)
  - [en](https://longbridge.com/en/news/283370239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283370239.md)
---

# A Top Wall Street Analyst 'Can't Ignore' Celldex Stock (CLDX)

Celldex (CLDX) stock was on the move Monday after the biopharmaceutical company received bullish coverage from five-star Barclays analyst Etzer Darout. The analyst hit CLDX stock with a double upgrade, now rating the stock as Overweight instead of Underweight. To go along with that, he boosted his price target to $45 from $25, representing a potential 30.25% upside for the shares.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to Darout, the firm "can't ignore" Celldex following the company's latest clinical trial results. The company provided positive results from its Phase 3 clinical trial of its chronic spontaneous urticaria treatment, barzolvolimab. The trial reached recruitment numbers ahead of schedule and posted strong results in Q4 2025. Darout argued this showed strong demand for barzolvolimab.

All of the recent clinical updates from Celldex have been positive, which has won over Darout. Investors have taken note of this, as he was one of the few Wall Street analysts who was still bearish on the stock prior to today's update.

## **Celldex Stock Movement Today**

While Celldex stock rallied in premarket trading on Monday, the shares gave up those gains after the opening bell. This has the stock down slightly this morning. Even so, the shares have increased 27.21% year-to-date and 82.42% over the past 12 months.

CLDX stock trading activity today saw some 95,000 shares change hands. This is below the stock's three-month average daily trading volume of about 1.17 million shares.

### Related Stocks

- [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment](https://longbridge.com/en/news/282801298.md)
- [Celldex Therapeutics Prices $300 Mln Public Offering Of Shares At $29/shr; Stock Down](https://longbridge.com/en/news/281470537.md)
- [Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX](https://longbridge.com/en/news/279153839.md)
- [Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum](https://longbridge.com/en/news/279161068.md)
- [Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results](https://longbridge.com/en/news/277110467.md)